这是全球领先的生物制药企业阿斯利康在山东青岛吸入气雾剂生产供应基地，该基地总投资额达七点五 亿美元。新华社记者 李紫恒摄 近日，经国务院同意，国家发展改革委、商务部全文发布《鼓励外商投资产业目录（2025年版）》（以 下简称《鼓励目录》），自2026年2月1日起施行。 《鼓励目录》是中国重要的外商投资促进政策，也是重要的外资产业和区域政策。修订出台新版《鼓励 目录》，是更大力度吸引和利用外资的重要举措。分析普遍认为，《鼓励目录》给外资企业坚定投资中 国增添更多信心。 2026年，中国将对外资企业释放怎样的"磁吸力"，外资企业在中国将获得怎样的新机遇？本报采访中国 现代国际关系研究院副院长张健和中国人民大学重阳金融研究院研究员刘英，对相关问题进行解读。 信心持续增强，结构加速调整 外资企业在华投资总体呈现质升量稳的特征。向高技术产业和以研发中心、创新中心为代表的高技术服 务业倾斜，成为外资企业在华投资的新趋势 【观察】 全球知名会计师事务所毕马威日前发布调查报告《2025年跨国企业中国展望》显示，2025年在中国运营 的跨国企业中，有3/4维持或增加了投资。 该报告还显示，除多数企业维持或加码投资外，本地化布局 ...

Group 1 - China's actual use of foreign investment increased by 26.1% year-on-year in November, with a total of 61,207 new foreign-invested enterprises established in the first 11 months, marking a 16.9% increase [1] - By the end of June this year, China's actual use of foreign investment during the "14th Five-Year Plan" period reached $708.73 billion, achieving its target six months ahead of schedule [1] - The resilience and improving structure of China's foreign investment attraction are evident, making it a favored destination for foreign capital [1] Group 2 - In the first 11 months of this year, actual foreign investment in China's high-tech industries reached 221.26 billion yuan, significantly contributing to the total foreign investment [2] - The e-commerce service industry, medical instruments and equipment manufacturing, and aerospace manufacturing saw foreign investment growth rates of 127%, 46.5%, and 41.9% respectively, indicating a shift towards higher-quality investment [2] - Foreign companies are increasingly recognizing opportunities in China, with significant investments in artificial intelligence, new energy, biomedicine, and green transformation sectors [2] Group 3 - The core attractions for foreign investment in China include an open innovation ecosystem, a complete industrial system, and rich application scenarios [3] - From 2013 to 2023, R&D expenditures by multinational companies in China increased by 86.5%, reflecting a shift from technology transfer to joint R&D and co-building industrial ecosystems [3] - The "14th Five-Year Plan" suggests new deployments to create new advantages in attracting foreign investment, with an improving business environment and high-quality development expected to provide broader opportunities for foreign enterprises [3]

Group 1 - China's actual use of foreign investment increased by 26.1% year-on-year in November, with a total of 61,207 new foreign-invested enterprises established in the first 11 months, marking a 16.9% increase [1] - By the end of June, China's actual use of foreign investment during the 14th Five-Year Plan period reached $708.73 billion, achieving its $700 billion target six months ahead of schedule [1] - The resilience and improving structure of foreign investment in China are evident, making it a favored destination for foreign capital despite global challenges [1] Group 2 - In the first 11 months, actual foreign investment in China's high-tech industries reached 221.26 billion yuan, significantly contributing to the total foreign investment [2] - The e-commerce services, medical instruments manufacturing, and aerospace equipment manufacturing sectors saw foreign investment growth rates of 127%, 46.5%, and 41.9%, respectively [2] - Foreign companies are increasingly recognizing opportunities in China, with significant investments in artificial intelligence, new energy, biomedicine, and green transformation sectors [2] Group 3 - The core attractions for foreign investment in China include an open innovation ecosystem, a complete industrial system, and rich application scenarios [3] - From 2013 to 2023, R&D expenditures by multinational companies in China increased by 86.5%, reflecting a shift from technology transfer to joint R&D and co-building industrial ecosystems [3] - Companies like Schneider Electric and Bayer are leveraging China's innovation capabilities, with significant contributions to global product development and market applications [3]

12月24日，有一只新股上市，为科创板的健信超导（688805.SH）。该公司成立于2013年12月11日，主 要从事医用磁共振成像（MRI）设备核心部件的研发、生产和销售，主要产品包括超导磁体、永磁体和 梯度线圈，这三大类部件占MRI设备核心部件成本的比例在50%左右。 打新早知道 Est Un Descrip | | | 今日上市 | | | --- | --- | --- | --- | | | 688805.SH 健信超导 | | | | 发行价(元/股) | 机构报价(元/股) | 市值(亿元) | 所属行业 | | 18.58 | 18.89 | 31.15 | 医疗仪器设备及器 | | | | | 械制造 | | 发行市盈率 | 行业市盈率 | 可比公司 | 可比公司动态市盈率 | | | | 联影医疗 | 60.39 | | 61.97 | 31.79 | 辰光医疗 | 亏损 | | | | 奕瑞科技 | 40.38 | | | 业绩情况 | | | | 5.0 4.5 | | | 50% | | 4.0 | | | 40% | | 3.5 3.0 - | | | 30% | 不过，当前健信超 ...

具体来看，前11个月，我国实际使用外资金额6931.8亿元，同比下降7.5%，较前10个月降幅收窄2.8个百分点。 央视网消息：中国商务部数据显示，11月份，中国实际使用外资同比增长26.1%，实际使用外资金额和新设立外商投资企业数量 均保持较快增长，显示中国仍然是受外资企业青睐的投资目的地。 引资结构持续优化。前11个月，生产性服务业实际使用外资占全国实际使用外资比例为63.5%，较2024年同期提高4.7个百分点； 电子商务服务业、医疗仪器设备及器械制造业、航空航天器及设备制造业实际使用外资同比分别增长127%、46.5%、41.9%。 新设立外商投资企业数量保持较快增长态势。前11个月，全国新设立外商投资企业61207家，同比增长16.9%；11月当月新设立外 商投资企业7425家，同比增长35.3%。 引资来源地更加多元化。瑞士、阿联酋、英国实际对华投资同比分别增长67%、47.6%、19.3%。 ...

12月15日，可申购科创板的健信超导(688805.SH)。该公司成立于2013年12月11日，主要从事医用磁共 振成像(MRI)设备核心部件的研发、生产和销售，主要产品包括超导磁体、永磁体和梯度线圈，这三大 类部件占MRI设备核心部件成本的比例在50%左右。 打新早知道 公司是全球最大的超导磁体独立供应商 注:机构报价为剔除无效报价和最高报价后,公募基金、社保基金、养老金、年金基金、保险资金和合格境外投 资者的报价中位数。 据招股书介绍，健信超导是国内最早规模化生产高场强超导磁体的厂商之一，并作为独立供应商保障了 国产磁共振产业的核心部件批量供应，有力推动了MRI设备国产化率提升。 目前，健信超导已形成包括1.5T零挥发超导磁体、1.5T无液氦超导磁体、3.0T零挥发超导磁体和开放式 零挥发超导磁体在内的丰富产品矩阵，成为全球磁共振行业内排名第一的超导磁体独立供应商。 同时，作为全球领先的专业磁共振核心部件供应商，健信超导已与国内外知名MRI设备厂商如日本富士 胶片集团、美国GE医疗、意大利百胜医疗、万东医疗（600055）、深圳安科、联影医疗、福晴医疗等 建立了紧密的合作关系，并通过海外子公司布局及运输过 ...

12月15日，可申购科创板的健信超导（688805.SH）。该公司成立于2013年12月11日，主要从事医用磁 共振成像（MRI）设备核心部件的研发、生产和销售，主要产品包括超导磁体、永磁体和梯度线圈，这 三大类部件占MRI设备核心部件成本的比例在50%左右。 打新早知道 Est Un Descrip | 今日申购 | | | | | --- | --- | --- | --- | | 688805.SH 健信超导 | | | | | 发行价(元/股) | 机构报价(元/股) | 市值(亿元) | 所属行业 | | 18.58 | 18.89 | 23.37 | 医疗仪器设备及器 | | | | | 械制造 | | 发行市盈率 | 行业市盈率 | 可比公司 | 可比公司动态市盈率 | | 61.97 | 31.79 | 联影医疗 | 61.96 亏损 | | | | 展光图疗 | | | | | 奕瑞科技 | 38.94 | | 业绩情况 | | | | 50% 5.0 4.5 40% 4.0 3.5 30% 3.0 20% 2.5 2.0 10% 1.5 1.0 0% 0.5 -10% 0.0 2022年 ...

本报北京11月22日电 （记者罗珊珊）记者从商务部获悉：今年前10月，全国新设立外商投资企业53782 家，同比增长14.7%；实际使用外资金额6219.3亿元。 从行业看，制造业实际使用外资1619.1亿元，服务业实际使用外资4458.2亿元。高技术产业实际使用外 资1925.2亿元，其中，电子商务服务业、医疗仪器设备及器械制造业、航空航天器及设备制造业实际使 用外资同比分别增长173.1%、41.4%、40.6%。 关注公众号：人民网财经 从来源地看，阿联酋、英国、瑞士实际对华投资同比分别增长48.7%、17.1%、13.2%（含通过自由港投 资数据）。 《 人民日报 》（ 2025年11月23日 01 版） (责编：胡永秋、杨光宇) ...

Investment Rating - The investment rating for the company is "Accumulate" (首次) [1][9] Core Insights - The company is a pioneer in the field of ultra-low temperature storage for biological cells, breaking foreign monopolies and focusing on technological innovation and market expansion [6][30] - The company has achieved a revenue of 1.5 billion yuan in the first half of 2025, with a year-on-year growth of 2.16%, and a net profit of 11.05 million yuan, reflecting a 5.94% increase [9][31] - The domestic medical device market is projected to reach 1.35 trillion yuan in 2024, with a compound annual growth rate of 7.53% from 2025 to 2030 [9][31] Company Overview - The company, established in 2002, is backed by Changhong Group and supported by the Chinese Academy of Sciences, focusing on ultra-low temperature storage [9][15] - It has received numerous accolades, including being recognized as a national-level "Little Giant" enterprise and winning the National Technology Invention Award [19][23] - The company has a diverse product portfolio, including ultra-low temperature storage boxes and laboratory equipment, with applications in medical, research, and biopharmaceutical fields [30][31] Financial Performance - Revenue projections for 2025-2027 are 320.91 million, 356.79 million, and 406.46 million yuan, with respective growth rates of 8.50%, 11.18%, and 13.92% [7][9] - The net profit for the same period is expected to be 25.22 million, 29.55 million, and 32.70 million yuan, with growth rates of 39.43%, 17.19%, and 10.64% [7][9] - The company's gross margin is reported at 36.67%, with a net margin of 7.35% for the first half of 2025 [9][31] Industry Analysis - The medical device industry is driven by policy and demand, with a significant push for domestic alternatives [11][30] - The market for biological low-temperature storage equipment is expected to grow from 6.772 billion yuan in 2022 to 21.543 billion yuan by 2028 [9][31] - The company is positioned to benefit from increasing demand for medical equipment in rural areas and supportive government policies [9][31] Product and Technology - The company has developed a comprehensive range of products, including ultra-low temperature storage devices and laboratory equipment, covering temperature ranges from -196°C to 8°C [30][31] - It has a strong focus on R&D, with 11.19% of revenue allocated to research, resulting in 436 patents as of the end of 2024 [9][45] - The company aims to enhance its technological capabilities and expand its product offerings in the ultra-low temperature storage sector [42][45]

Core Viewpoint - In the first three quarters of this year, China has seen a significant increase in foreign investment, with a total of 48,921 new foreign-invested enterprises established, marking a year-on-year growth of 16.2% [1] Group 1: Foreign Investment Statistics - In September, the actual use of foreign capital increased by 11.2% year-on-year [1] - The manufacturing sector attracted 150.9 billion yuan in actual foreign investment [1] - The service sector attracted 410.9 billion yuan in actual foreign investment [1] Group 2: High-Tech Industry Investment - The high-tech industry received 170.8 billion yuan in actual foreign investment [1] - Specific sectors within high-tech saw substantial growth: e-commerce services grew by 155.2%, aerospace equipment manufacturing by 38.7%, and medical instruments manufacturing by 17% [1]